Overview

Study of Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics of LNP023 in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Status:
Active, not recruiting
Trial end date:
2023-06-07
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the efficacy of LNP023 in patients with PNH, showing signs of active hemolysis despite treatment with SoC (defined as an antibody with anti C5 activity).
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals